Aggregated from the cited literature below. We summarize sources — we don't author claims.
CJC-1295 is described as a long-acting growth-hormone-releasing hormone (GHRH) analog. Clinical research in healthy adults reported sustained, dose-dependent increases in circulating growth hormone (GH) and insulin-like growth factor I (IGF-I) after subcutaneous administration, with effects persisting for days and no serious adverse reactions reported in the studied cohorts.
Mechanism (as reported)
One study investigated CJC-1295 as a long-acting GHRH analog intended to stimulate GH secretion, which in turn was associated with increases in IGF-I levels in healthy adults (PMID 16352683). Reviews also describe growth-hormone secretagogues (including CJC-1295) as activating IGF-1 signaling in the context of regenerative mechanisms discussed for orthopaedics (PMID 41490200).
Key findings (each cites a source)
In healthy adults, a study reported that CJC-1295 produced dose-dependent increases in mean plasma GH concentrations lasting 6 days or more after a single injection, and dose-dependent increases in mean plasma IGF-I lasting 9–11 days. [PMID 16352683]
The same study estimated CJC-1295 plasma half-life to be 5.8–8.1 days and reported that after multiple doses, mean IGF-I levels remained above baseline for up to 28 days. [PMID 16352683]
In that healthy-adult study, no serious adverse reactions were reported and CJC-1295 was described as safe and relatively well tolerated within the study conditions. [PMID 16352683]
A study on identification of illicit preparations reported that an unknown pharmaceutical preparation contained a 29-amino-acid peptide with a C-terminal amide, with the proposed sequence consistent with CJC-1295 (a growth-hormone-releasing peptide). [PMID 21204297]
A detection-focused study in equine plasma reported an LC-MS/MS confirmation approach after immuno-affinity capture and tryptic digestion to identify CJC-1295, describing challenges in detecting CJC-1295-protein conjugates and reporting identification sensitivity down to 180 pg/mL in 1 mL of equine plasma. [PMID 30938069]
A study investigating anti-doping detection reported in vitro metabolism and detection development for four larger GHRH synthetic analogs including CJC-1295, identifying metabolites and developing an LC-MS/MS method; limits of detection for target peptides were generally 1 ng/mL or less in fortified urine. [PMID 34665524]
A narrative review described the use of peptides in orthopaedics and noted that CJC-1295 combined with ipamorelin showed improved maximum tetanic tension in a murine model with glucocorticoid-induced muscle loss, while emphasizing that the findings were limited to animal studies. [PMID 41476424]
A narrative review on orthopaedic therapeutic peptides discussed mechanistic signaling pathways and included CJC-1295 among growth hormone secretagogues that are discussed as activating IGF-1 signaling in the context of orthopaedic relevance. [PMID 41490200]
Vendor test rankings (20)
Vendors ranked by their independent third-party test grade for CJC-1295, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.4% across 391 tests. Not our verdict.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · The Journal of clinical endocrinology and metabolism · 2006 · PMID 16352683
FAQ
What is CJC-1295?
CJC-1295 (CJC 1295, 62RC32V9N7, DTXSID501027567) is classified under ghrh analogs, sold for research use only and not approved for human consumption. Research goals associated with it include gh axis support.
Is CJC-1295 FDA-approved?
No. CJC-1295 is sold for research use only and is not approved for human consumption.
What does the research on CJC-1295 say?
peptideone aggregates 8 references from PubMed for CJC-1295. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.